Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16948094 | 0.88 | MAPK1 (0.33) | — | |
| SCHEMBL5597013 | 0.85 | GNAI3 (0.34) | — | |
| SCHEMBL9801300 | 0.83 | GRM5 (0.30) | — | |
| SCHEMBL2744441 | 0.82 | KDM4E (0.41) | KDM4E | |
| SCHEMBL2744458 | 0.82 | GRM2 (0.31) | — | |
| SCHEMBL23254096 | 0.82 | — | — | |
| SCHEMBL3176003 | 0.82 | KEAP1 (0.36) | — | |
| Bromide SCHEMBL31466612 | 0.80 | — | — | |
| SCHEMBL6132878 | 0.79 | GRM5 (0.30) | — | |
| SCHEMBL16126019 | 0.79 | CYP1A2 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3915987-A1 | ALKYL-AMINE HARMINE DERIVATIVES FOR PROMOTING BONE GROWTH | Osteoqc Inc. (CA) | 2021-12-01 | — | — | EP | disclosed |
| CN-112574413-A | Toughening modified marine polyimide foam material and preparation method thereof | 江苏中科聚合新材料产业技术研究院有限公司 | 2021-03-30 | — | — | CN | disclosed |
| US-20170298059-A1 | COMPOUNDS FOR BONE GROWTH | OSSIFI THERAPEUTICS LLC | 2017-10-19 | — | — | US | disclosed |
| US-9540365-B2 | Compounds for bone growth | OSTEOQC INC. (CA) | 2017-01-10 | — | — | US | disclosed |
| US-20140288068-A1 | ALKYL-AMINE HARMINE DERIVATIVES FOR PROMOTING BONE GROWTH | OSSIFI INC. (US) | 2014-09-25 | — | — | US | disclosed |
| US-8563540-B2 | Pyrido[3,2-d]pyrimidine PI3K delta inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| US-20130225557-A1 | PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-8440651-B2 | Pyrido[3,2-d]pyrimidine PI3K delta inhibitor compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2013-05-14 | — | — | US | disclosed |
| US-8173650-B2 | Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use | GENENTECH, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-20100305096-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | GENENTECH, INC. | 2010-12-02 | — | — | US | disclosed |
| US-4992150-A | Telomer with alpha-olefin;oil and fuel additive | NIPPON OIL CO, LTD. (JP) | 1991-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225557-A1 | PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CB | KDM4E 4147/4885 |
| US-20170298059-A1 | COMPOUNDS FOR BONE GROWTH | FGF1, FGF2, BMP2 | KDM4E 2795/4885 |
| US-20140288068-A1 | ALKYL-AMINE HARMINE DERIVATIVES FOR PROMOTING BONE GROWTH | TPH1, TPH2, HTR5A | KDM4E 701/4885 |
| US-20100305096-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | PIK3CA, PIK3R2, PIK3CD | KDM4E 4647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.